ITM secures supply deal with Clovis Oncology

By AuntMinnie.com staff writers

October 19, 2021 -- German radiopharmaceutical firm ITM Isotope Technologies Munich has signed an agreement to supply its EndolucinBeta no-carrier-added lutetium-177 radiopharmaceutical precursor to Clovis Oncology.

Under the five-year deal, Clovis will utilize EndolucinBeta for the clinical development of its FAP-2286 fibroblast activation protein (FAP)-targeted radionuclide therapy candidate, according to the companies. FAP-2286 consists of a targeting peptide that binds to FAP and a site that can be used to attach radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use, the companies said.

FAP-2286 is currently being investigated in a phase I/II study in patients with advanced solid tumors. Additional terms of the agreement were not disclosed.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: